Barclays analyst Steve Valiquette lowered the firm’s price target on CVS Health to $89 from $90 and keeps an Overweight rating on the shares. The analyst remains cautious on cost trend for Q2, saying data points from Medicare managed care suggests continuation of strong utilization from Q1.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CVS: